Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAC01-CLDN18.2 in CLDN18.2+ Solid Tumors
NCT05862324Phase 2Active, not recruiting
- Sponsor
- Triumvira Immunologics
- Start
- Aug 2023
- Primary completion
- Aug 2027
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of TAC01-CLDN18.2 in gastric cancer (GC), esophageal adenocarcinoma (EAC), pancreatic ductal adenocarcinoma (PDAC) and 5 more, sponsored by Triumvira Immunologics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) at 24 months, Overall Response Rate at 24 months and 4 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
TAC01-CLDN18.2
03
Conditions
gastric cancer (GC)esophageal adenocarcinoma (EAC)pancreatic ductal adenocarcinoma (PDAC)ovarian cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05862324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862324.